Plasma components: properties, differences, and uses.

Area of Science:

• Transfusion Medicine
• Hematology
• Biotechnology

Background:

• Plasma components are critical for managing coagulation factor deficiencies and in therapeutic plasma exchange for conditions like thrombotic thrombocytopenic purpura.
• Key transfused products include fresh-frozen plasma (FFP), plasma frozen within 24 hours (FP24), cryoprecipitate-poor plasma (CPP), and thawed plasma.
• FP24, CPP, and thawed plasma exhibit reduced levels of labile coagulation factors compared to FFP.

Purpose of the Study:

• To review the general uses and types of plasma components transfused.
• To discuss pathogen reduction technologies and their availability.
• To examine the implications of pathogen-reduced plasma on regulatory requirements for novel plasma products.

Main Methods:

• Literature review of plasma component uses and available technologies.
• Analysis of coagulation factor content in different plasma products.
• Examination of pathogen reduction techniques and their impact on plasma quality.
• Assessment of regulatory landscapes in Europe and the United States regarding plasma products.

Main Results:

• FFP, FP24, CPP, and thawed plasma are primary transfusion products, with FP24, CPP, and thawed plasma having decreased labile coagulation factors.
• Pathogen reduction technologies (solvent/detergent, UV irradiation) are used in Europe but not the US.
• Pathogen-reduced plasma may exhibit diminished coagulant and anticoagulant factor levels compared to FFP.
• Clinical data on pathogen-reduced plasma has prompted the US FDA to consider stringent requirements for new plasma products.

Conclusions:

• Different plasma products vary in their coagulation factor content, necessitating careful selection for clinical applications.
• Pathogen reduction technologies offer potential safety benefits but may alter plasma composition.
• Regulatory hurdles in the US may impede the development and adoption of novel pathogen-reduced plasma products.